Alkem Laboratories Limited — Q2 FY25
Alkem's Q2 FY25 PAT grew 11% YoY to INR 6,886 million, driven by cost controls and a favorable product mix.
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q1 FY25
Domestic business growth in line with IPM (8-10%)
India business expected to grow in line with the Indian pharmaceutical market, which is projected at 8-10%.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q1 FY25
US business single-digit growth with new launches
US business expected to see single-digit growth, with Dabigatran contributing meaningfully from Q3/Q4.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1